Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Artelo Biosciences, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- +1 vs. Q1 2025
- Shares held
- 16.6K
- −70.0K (−80.8%) vs. Q1 2025
- Total value
- $220.1K
- +$144.4K (+190.5%) vs. Q1 2025
- New holders
- 4
- 0 more added
- Sold out
- 3
- 5 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.4K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $992.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 16,032 | $212.7K | 0.00% | −10,730−40.1% | Reduced |
| Tower Research Capital LLC (TRC) | 447 | $5.93K | 0.00% | −3,456−88.5% | Reduced |
| UBS Group AG | 89 | $1.18K | 0.00% | −12,683−99.3% | Reduced |
| Citigroup Inc | 9 | $119 | 0.00% | +9 | New |
| Bank of America Corp | 5 | $66 | 0.00% | −22−81.5% | Reduced |
| Morgan Stanley | 4 | $53 | 0.00% | −16−80.0% | Reduced |
| FMR LLC | 1 | $13 | 0.00% | +1 | New |
| Danske Bank A/S | 1 | $13 | 0.00% | +1 | New |
| Royal Bank of Canada | 2 | $0 | 0.00% | +2 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −22,706−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −20,388−100.0% | Sold out |
| Rothschild Investment LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |